@FullMoonFever Another chart request if you are up for it please thanks in advance, page-2. Join the HotCopper ASX share market forum today for free. Postcard to ShareholdersIXC (ASX) Ann: Trading Halt - HotCopper. IXC has not had a decent bounce at all as yet, maybe still some sellers lurking. 0¢ Sentiment: Buy Disclosure: Held Bumping up this thread as $3. Too many factors to make an educated appraisal of buyout pre-Phase 2 or post Phase 2. (IXC) - see HotCopper and other bloggers' predictions - TipRanks. 26 area could be wrong and it could go for example to $3. IXC (ASX) Ann: Trading Halt - HotCopper. ASX - General. Interexchange carriers (IXCs) own or share the various high-bandwidth, fiber-optic trunk lines that cross the country and provide high-speed switched digital services for voice, data, and video communication. " Seems a bit rough, anyone would think they are trying to minimise the number of SH who 'attend' the AGM. Charts. There can't be many left who have a positive association with this stock (apart from seed investors), so I don't think token $10-20k director purchases will change anything. . Advertise on HotCopper. Created with Sketch. Interexchange Carrier, also known as IXC, is a telco that mainly provides long-distance communication services. Market . 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. ASX - Day Trading. , page-136. . IXC Price at posting: 79. 15M !Invex to Present at Bell Potter Healthcare ConferenceNotice of Annual General Meeting/Proxy Form, page-3. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. The Chart: An Opportunity at these Levels?Timeline Annotations of the IXC Chart Story Thus Far- IXC IPO'd in mid 2019 with Phase II data due Mid 2020,. ASX - Day TradingA new thread to put trading comments / reasoning / opinions in. ASX - By Stock. ASX - Day Trading. ASX - By Stock. How many friends and family got out after the last announcementshould have been released at the same time, page-34. ASX - By Stock. 2. . . ASX - By Stock. A handy 10 bags from here with seemingly little risk. Created with Sketch. Target our investor community with our suite of Hotcopper Advertising opportunities. Learn more. June 29 (Reuters) - Invex Therapeutics Ltd (IXC) : INVEX RECEIVES UK APPROVAL TO COMMENCE PHASE III TRIAL CLINICAL TRIAL FOR PRESENDIN DRUG FOR. Posted without a title, my bad hahaI was going for something like Invex - How much is it worth, when Phase 2 results hit in March 2020?Got this from IXC by email today. , page-5. 0¢ Sentiment: Buy Disclosure: Held. ASX - By Stock. ASX - Day TradingMEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZCreated with Sketch. Last research or update on this I listened to was by FiftyOneCapital. Australia's largest stock trading and investment forum Australia's #1 stock forumInvestor PresentationMRDMount Ridley Mines REE Project: Drilling confirms continuous high-grade mineralisation. So your thesis is right on a long time time frame. Loading. Liked by Jackie Cox-Ziegler, CPHR. Met primary endpoints for phase 2 trials. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-6. Learn how it impacts everything we do. ASX - By Stock. Most bio's get acquired on P2 readouts, if results are strong early here. IXC could also be worth $14 on a successful trial and licensing deal (or takeover). To work out how much Presendin is worth, we can look at the costs of IIH to the American health care system. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Given that IXC's Chief Scientific Officer, Alex Sinclair, is the author of IIH treatment guidelines, the introduction of an effective medication to the market would likely lead to a rapid integration of Presendin into treatment protocols. Charts. Created with Sketch. , page-6. Market . ASX - Day TradingChange in substantial holding. . Trading HaltIXC Valuation Report MST. You’d be surprised the volume that comes in when this happenes, but by that stage you’ll be 100% up whilst the opportunity cost traders will be trying to catch the move up. Anyone had a look at this or put an application in for some stock in the IPO?, page-2. sentiment based on opinions from HotCopper and others. All IMO IXC Price at posting: 37. AX stock on Yahoo Finance. . . . 5¢ Sentiment: Buy Disclosure: HeldAt the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!If you're a poster who is inclined to track TA,. Is it just me or has IXC gone very quiet. Created with Sketch. ASX - Day Trading It is certainly an interesting case study regarding management strategy; that noted strategy would work during fair or bullish markets as participants are acting rationally (and by sticking to their knitting during Covid Crash the IXC share price bounced back heavily with Phase II results - so perhaps thats what they were thinking would happen. , page-2. Forex. ASX - Short Term Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical developmentHREC and TGA Approval to Commence Phase 3 in AustraliaHi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. 8,369 likes · 140 talking about this · 1,407 were here. 54am 24/11/2023 ? HotCopper has news, discussion, prices and market data on INCA MINERALS LIMITED. ASX - By Stock. Market . Created with Sketch. Hi All, I have decided to make an IXC broker data thread, as my PAR broker data thread was very well received. ASX - By Stock. 69KBThis doesn't mean that IXC is doomed, just that things are more a gamble than an investment at the moment. . . Toubani Resources is an exploration and development company with a focus on developing a gold platform in West Africa. My understanding is that NEU went from around $1. IXC Valuation Report MST. Created with Sketch. Click for more information. ASX - Day Trading. ASX - By Stock. . IXC Price at posting: 38. It was well aware of the claims made, released such information in the prospectus (and still had a hugely successful IPO), and would have done their due diligence before entering into any agreements with the University. 3¢. . ASX - By Stock. 0¢ Sentiment: Buy Disclosure: HeldHotCopper has news, discussion, prices and market data on GENESIS MINERALS LIMITED. Cannot wait. I think IXC has the potential to do better. Created with Sketch. ASX - By Stock. Australia's largest stock trading and investment forum Australia's #1 stock forumInvex Successfully Concludes Protocol Assistance with EMA, page-2. Forums. . is 19. $100-200k might be the minimum for the market to take notice. Share “Exercise Price Subject to paragraph (j), the amount payable upon exercise of each Option will be the 50% premium to the 30 day VWAP immediately prior to the Meeting (Exercise Price). . Advertise on HotCopper. 5¢ Sentiment: Buy Disclosure: Held Created with Sketch. Some people like to gamble on stocks, others invest. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 59 before first real pull back (those lines will be used in the future, they always set it up for that reason, being $3. Some people like to gamble on stocks, others invest. Invex Therapeutics Ltd. Ceasing to be a substantial holderAustralian finance news, stock quotes, currency information and blogsQuarterly Activities/Appendix 4C Cash Flow ReportInvex Granted European Patent for Exenatide in Hydrocephalus. ASX - Day Trading. 59). Created with Sketch. . wonder if the GLP-1 agonist referred to in this media release. , page-17. GW Ixc once again showing why you are the best mgmt team on the ASX . 1 Upvote. ASX - Day TradingCreated with Sketch. US data averaged $2314 per person in direct medical care, the total average direct cost per IIH admission was 4x that or $9256. ASX - General. 6% $DLM 50. Commodities. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-8. Not sure what software this is but is there a way you can send the document itself, is a tad tough to read it with the photo you sent, if not all good, page-4. At that time the total costs of IIH exceeded $444,000,000. Notification of cessation of securities - IXC. 63%. ASX - Day TradingApril 20 (Reuters) - Invex Therapeutics Ltd (IXC) : MINISTRY OF HEALTH APPROVAL FOR IIH EVOLVE CLINICAL TRIAL IN ISRAELInvestor Presentation, page-2. ASX - Day Trading. ASX - Day Trading0. 147,415. Market open. Currency in USD 38. Also took placement stock @$1. Trading HaltIXC Valuation Report MST. 375,000. Forums. Jellyroll, arkangel, CD, balkanbroker to name a few have laid out some pretty compelling thesis' on where IXC will be heading. Forums. Investor PresentationI would be worried about holding IXC if they had no more cash. Market . A neurosurgeon from Mercer Island and a noted mountaineer from Spokane, Washington, were killed on February 4, 1986, when. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. 3¢. ASX - By Stock. ASX - Day TradingCreated with Sketch. ASX - By Stock. Share I've got no issues with it. 1073084. gov and there is lots of good information about the trial. ASX - Day Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. It certainly has been a hard few months for the biotech sector with PEB, NYR, NOX and now IXC all having prangs. Created with Sketch. Last updated 10. . I think having this out we can discuss on the way. Thought that this would be worthy of its own thread, a great starting place for those new to IXC and arguably the best presentation to date, Worth a. Given that IXC's Chief Scientific Officer, Alex Sinclair, is the author of IIH treatment guidelines, the introduction of an effective medication to the market would likely lead to a rapid integration of Presendin into treatment protocols. Theres alot of breakdowns above that are yet to be backtested. ASX - General. Notice of Quarterly Investor Call. *Close price adjusted for splits. ASX - General. , page-6. Market . Market . 54pm 22/11/2023 ? HotCopper has news, discussion, prices and market data on INVEX THERAPEUTICS LTD. Created with Sketch. Results of MeetingFor those curious about the T20 moves over the last 2 months of available data;Underlined = UnchangedGreen = Positive ChangeRed = Negative ChangeDYOR, not. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. ASX - Day TradingInvex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. com. ASX - General. But lets not talk about NSB here, we are here to see progress with IXC. Share A few weeks ago in the lead up to the Phase 2 results invex included this slide on their slide deck - 'average 42 million increase in market cap after positive Phase 2 results'. Forex. Folks say we are pioneers of craft ice cream in Victoria. . Wouldn’t surprised me if they turn this company into something else if he keeps buyingCreated with Sketch. Discover historical prices for IXC. ASX - General. Loading interactive chart. ASX - Day TradingAnother day…another approval. pdfGreat to see initiation of research from MST today, click the link to read the full report or read the first page in post. International Markets. Created with Sketch. Created with Sketch. 5¢ Sentiment: Hold Disclosure: Held IXC Valuation Report MST. . 50%. RAC went from 30 cents to $4 in the space of 5 months PAR went from 30 cents to $4 in the space of 1 and half years NEU went from $1. 392 10/12/19 20:43 Post #: 41898691 Share @FullMoonFever Another chart request if you are up for it please thanks in advance IXC Valuation Report MST. Chairman's Address to Shareholders and PresentationHi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. . ASX - By Stock. **Close price adjusted for splits and dividend and/or capital gain distributions. Latest Posts. ASX - General. Andrew Forrest , or his entities have been involved with IXC since inception. The Phase III raise encompassed the costs for a go-it-alone reformulation strategy, with Bell Potter suggesting in a Q&A with IXC that they saved $5-6M in going with Peptron for their reformulation supply/manufacturing, alongside 12 months in time. Created with Sketch. , page-35. ASX - Day Trading. . . These are 2007 numbers. IXC Price at posting: 44. Appendix 4C - quarterly* or having a go at doing so, page-30. Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-3. Get the edge as an investor: Subscribe to our daily newsletter for EXCLUSIVE insights into HotCopper!. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Forgot Client ID or Password? If you're a CommBank customer, you can access CommSec from Netbank. Charts. ASX - Day Trading. Top 20 remains holding 58% compared to 58. Created with Sketch. $45M MC $30M Cash and a $1. Hopefully they hit the miracle, at least I get something back from this if it goes balls up which in the bio world at the moment is highly likely. ASX - By Stock. But there are two key factors that make me hope that the BoD pursues the Phase 2, but I worry that JP and co will push for the. . I bought the chart from base lows looking for a trade. ASX - By Stock. View daily, weekly or monthly formats back to when Invex Therapeutics Ltd stock was issued. INVEX THERAPEUTICS LTD (ASX:IXC) - IXC chart, page-9 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum Forums ASX - By Stock IXC. Advertise on HotCopper. , page-2. They'll still have 14-15M in cash plus ODD for TBI in Europe and soon, one from the FDA, with plans for a P2 TBI study. Market . Latest Posts. That is fair and as I mentioned in my initial post when buying, the business is worth the cash in ST. Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious. . , page-5. The announcement was certainly a setback but we're not dead in. . @FullMoonFever Another chart request if you are up for it please thanks in advance, page-4. All the latest Invex Therapeutics Ltd (ASX:IXC) share price movements, news, expert commentary and investing advice from The Motley Fool Australia. I knew zero about the fundamentals of IXC. A new thread to put trading comments / reasoning / opinions in. Advertise. Created with Sketch. Join the HotCopper ASX share market forum today for free. 0 Million. More progress made towards the start of Phase III, we have now made it on to the clinicltrials. Hopefully that placement overhang will be removed today tomorrow and the share price will catch up. Quarterly Activities/Appendix 4C Cash Flow Report. Fully funded. ASX - By Stock. ASX - Day TradingCreated with Sketch. . Invex Therapeutics Ltd. Created with Sketch. ASX - By Stock. no point selling now. Hi Hot Copper, this will be a master thread for my daily posting of the Pharma Market Watchlist, please only keep commentary to the watchlist. ASX - By Stock. Daily bounced well off support and now slowly creeping upId like to see a range develop now between say 18 - 23 before next bit of news, page-517. ASX - Short Term Trading. Invex Therapeutics Limited (ASX:IXC) is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Notice of Annual General Meeting/Proxy FormInvex Receives Written Response from FDA on Type C MeetingNotification of cessation of securities - IXC. 7% #asx #ausbiz 23 Jun 2023 06:06:11Not been following IXC but it seems that this Orphan Drug Designation for TBI now have $0 value due to the other Phase III trial update and the company is. ASX - By Stock. Hi guys, after discussion with Tom I have kind of mapped out the timeline to what is to be achieved. British Columbia, Selkirk Mountains. IXC Valuation Report MST. Created with Sketch. Share Ok news not the greatest but I dont think its as bad as people gonna re-act (mainly retailers) Primary endpoint remains unchanged Protocol changes focus on reordering secondary endpoints - replacing PMD with the more. Probably been disappointed like all of us Created with Sketch. Charts. 0¢ Sentiment: Buy Disclosure: Held. Proposed listing date: 4 JULY 2019#Created with Sketch. Australian finance news, stock quotes, currency information and blogs Active Funds. Created with Sketch. @FullMoonFever Another chart request if you are up for it please thanks in advance, page-3. 1. 20 to $7. Given the quality of the posters on the IXC thread I am confident others will do the same. . 20. Created with Sketch. Latest Posts. is there any news release, or SP increasing due to only the market showing interestCreated with Sketch. 147,415. IXC Price at posting: 37. Target our investor community with our suite of Hotcopper Advertising opportunities. ASX - Day TradingIf anyone told me a year ago, "there is a chance IXC cant progress the trial and the management all get sacked" I would agree that there was a chance, but nullified to a 1-2% black swan and worth the upside return profile. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. . Invex Therapeutics Ltd. Created with Sketch. 0¢ Sentiment: Buy Disclosure: Held Created with Sketch. 0¢ Sentiment: Buy Disclosure: Held. ASX - By Stock. Latest Posts ForumsHalf Yearly Report and AccountsLooks like people are starting to wake up here and realise how bloody cheap IXC is. . Notice of Annual General Meeting/Proxy Form, page-2. IXC. Market . Invex Files Pre-IND/Type B Meeting Request with US FDAIXC is a long term play mate, not a daytraders plaything as too illiquid. . 1. ASX - Short Term Trading. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving. See page-34. ASX - Day TradingSomeone bought $500 stock today at 44 cents. 59 before first real pull back (those lines will be used in the future, they always set it up for that reason, being $3. . 0. 30 order I had out there for 2-3 weeks. . . IXC Valuation Report MST. a shell trading below cash backing, ripe. ASX - By Stock. Charts. Lucky for you all IXC still sits at only 60 cents. boolish Jellyroll hey. Created with Sketch. Good fundamental research starting points for IXC:Summary: IXC FactsheetMST Analyst Equity Research ReportFiftyOne Capital ReportPresentation - Tom Duthy. Update - Notification regarding unquoted securities - IXC. Forums. Invex Therapeutics Lists on ASX, page-3. **Close price adjusted for splits and dividend and/or capital gain distributions. As thread states post your questions here and let’s start compiling a list. Latest Posts. ASX - Short Term Trading. ASX - Day TradingCreated with Sketch. , page-4. Share "Online registration will open 30 minutes before the Meeting. Invex Receives Approval for Paediatric Plan from the EMA, page-3. ASX - By Stock. About 90 percent of the U. Invex to Present at Virtual ASX Small and Mid-Cap ConferenceHealth & BiotechMay 24, 2020|Tim BorehamSHAREFrom the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a. I'm talking about the period of the announcement about trials None of them moved apart from retailers that hosed out over 3 mill in shares. Latest Posts. 0% $ODM 35. Interexchange carriers (IXCs) own or share the various high-bandwidth, fiber-optic trunk lines that cross the country and provide high-speed switched digital services for voice, data, and video communication. Latest Posts Forums iShares Global Energy ETF (IXC) Add to watchlist NYSEArca - Nasdaq Real Time Price. 0. 10 cents a week and we will be at $2 plus in no time. 0 Great analysis. . Information. Created with Sketch. , page-3. Latest Posts. Join the HotCopper ASX share market. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving. ASX - Day TradingInitial FDA and EMA Advice on Presendin Development, page-2. Login to your CommSec account to buy. Market . 26 area could be wrong and it could go for example to $3. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical. Join HotCopper today. A new thread to put trading comments / reasoning / opinions in. ASX - General. 2 years ago biotech stocks were in vogue and hence NEU was fairly priced at $1. I find this very intriguing and positive that in last few weeks about 1. Probably been disappointed like all of usCreated with Sketch. IXC Valuation Report MST. Created with Sketch. ASX - Short Term Trading. , page-32. Im not expecting anything out of the ordinary apart from the fact thats its overdone and too undervalued at the stage its at. Latest Posts ForumsHalf Yearly Report and AccountsWith debt too expensive and lots of very discounted capital raisings especially in the microcap part of the market, I'd like to think that IXC can take advantage of the fact that they have cash. ASX - Day TradingTo name a few other biotechs that have gotten belted by the market of the last few months that have had decent bounces such as NOX, NYR and PEB. Last edited by ejjwj: 28/06/23. Forums. 06KBNotification of cessation of securities - IXC. Invex Therapeutics (ASX:IXC) is an Australian-based, late-stage biopharmaceutical development Company with issued patents and multiple orphan drug designations focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of. Spot on - filled the 1. ASX - By Stock. Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-2. ASX - By Stock.